Eli Lilly & Co

TL;DR

Eli Lilly's weight-loss drugs are driving substantial profit increases and market value growth.
The company is investing in AI for drug discovery through collaborations with biotech firms.
Eli Lilly is engaged in global negotiations regarding drug pricing, including with the UK's NHS.
Competition in the weight-loss drug market is intensifying, with Novo Nordisk as a key rival.
Regulatory bodies are monitoring potential side effects of weight-loss drugs like pancreatitis.
Pharmaceutical companies are exploring both injectable and oral formulations for weight-loss treatments.
Eli Lilly achieved a significant milestone by becoming the first pharmaceutical group to join the $1 trillion market cap club.
The US is looking to reduce the prices of obesity drugs offered on specific platforms.

Continuar leyendo el artículo original